Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus by Yubing Wang et al.
ORIGINAL RESEARCH
published: 10 January 2017
doi: 10.3389/fmicb.2016.02163
Frontiers in Microbiology | www.frontiersin.org 1 January 2017 | Volume 7 | Article 2163
Edited by:
Octavio Luiz Franco,
Universidade Católica de Brasília
(UCB), Brazil
Reviewed by:
Sérgio Alencar,
Universidade Católica de Brasília
(UCB), Brazil
Carina Elisei Oliveira,
Universidade Católica Dom Bosco
(UCDB), Brazil
*Correspondence:
Yi Jin
wizard.jin@163.com
Xiaoqing He
hexiaoqing.china@126.com
Rongling Wu
rwu@bjfu.edu.cn;
rwu@phs.psu.edu
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 02 September 2016
Accepted: 22 December 2016
Published: 10 January 2017
Citation:
Wang Y, Li X, Jiang L, Han W, Xie X,
Jin Y, He X and Wu R (2017) Novel
Mutation Sites in the Development of
Vancomycin- Intermediate Resistance
in Staphylococcus aureus.
Front. Microbiol. 7:2163.
doi: 10.3389/fmicb.2016.02163
Novel Mutation Sites in the
Development of Vancomycin-
Intermediate Resistance in
Staphylococcus aureus
Yubing Wang 1, Xiaoli Li 1, Libo Jiang 1, 2, Wentao Han 1, Xiangming Xie 1, Yi Jin 1, 2*,
Xiaoqing He 1, 2* and Rongling Wu 1, 2, 3*
1College of Biological Sciences and Biotechnology, Beijing Forestry University, Beijing, China, 2Center for Computational
Biology, Beijing Forestry University, Beijing, China, 3Center for Statistical Genetics, Pennsylvania State University, Hershey,
PA, USA
Increased use of vancomycin has led to the emergence of vancomycin-intermediate
Staphylococcus aureus (VISA). To investigate the mechanism of VISA development,
39 methicillin-susceptible strains and 3 MRSA strains were treated with vancomycin
to induce non-susceptibility, and mutations in six genes were analyzed. All the strains
were treated with vancomycin in vitro for 60 days. MICs were determined by the agar
dilution and E-test methods. Vancomycin was then removed to assess the stability of
VISA strains and mutations. Following 60 days of vancomycin treatment in vitro, 29/42
VISA strains were generated. The complete sequences of rpoB, vraS, graR, graS, walK,
and walR were compared with those in the parental strains. Seven missense mutations
including four novel mutations (L466S in rpoB, R232K in graS, I594M in walk, and
A111T in walR) were detected frequently in strains with vancomycin MIC ≥ 12 µg/mL.
Jonckheere-Terpstra trend test indicated these mutations might play an important
role during VISA evolution. After the vancomycin treatment, strains were passaged to
vancomycin-free medium for another 60 days, and the MICs of all strains decreased.
Our results suggest that rpoB, graS, walk, and walR are more important than vraS and
graR in VISA development.
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INTRODUCTION
Multiple antibiotic resistant Staphylococcus aureus continues to be one of the most
common pathogens of both hospital-associated and community-associated infections worldwide
(Klevens et al., 2007; Popovich et al., 2007; Hidron et al., 2008; Kallen et al., 2010).
Methicillin-resistant S. aureus (MRSA) infection, acquired immunodeficiency syndrome (AIDS)
and viral hepatitis B are the three major infectious diseases worldwide and pose a
serious threat to public health (Dantes et al., 2013). Vancomycin is the first-line antibiotic
therapy for MRSA infections (Sieradzki et al., 1999; Deresinski, 2005; Moellering, 2005).
However, increased use of vancomycin has led to the emergence of vancomycin-intermediate
S. aureus (VISA) (Hiramatsu et al., 1997b). Currently, the Clinical Laboratory Standards
Institute (CLSI) categorizes S. aureus as vancomycin susceptible (VSSA) (MIC ≤ 2
µg/mL), vancomycin intermediate resistant (4–8 µg/mL), and vancomycin resistant (VRSA)
(MIC ≥ 16 µg/mL) (Patel, 2014). VISA has been reported more frequently worldwide and
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has aroused considerable concern (Hiramatsu et al., 1997a, 2002;
Tenover and Moellering, 2007; Rishishwar et al., 2016).
VRSA emerged in 1997 due to acquisition of the vanA gene
from vancomycin-resistant enterococci (Hiramatsu et al., 1997a;
Chang et al., 2003). Previous studies indicated that spontaneous
mutations play important roles in the evolution of drug resistance
(Drlica, 2003; Andersson and Hughes, 2014). However, the
genetic mechanism of vancomycin resistance in VISA strains
has not been identified fully (Cameron et al., 2016). Several of
mutations in multiple genes and gene regulation systems are
needed to achieve a VISA phenotype. Several genetic alterations
in two-component regulatory systems have been reported to be
strongly associated with a VISA phenotype, including mutations
in the vraSR operon (Mwangi et al., 2007), graRS (Howden
et al., 2008b; Neoh et al., 2008; Cui et al., 2009), and walRK
(Howden et al., 2011; Shoji et al., 2011). VraS may serve as
a switch for the activity of the “cell wall stimulon” (Gardete
et al., 2012). The vraS I5N mutation was found to confer
heterogeneous vancomycin resistance when introduced into a
vancomycin-susceptible MRSA strain (Katayama et al., 2009).
The graR N197S mutation was suggested to convert strain
Mu3 into the VISA phenotype (Neoh et al., 2008). Howden
et al. confirmed that the T136I mutation in graS is also a key
mediator of vancomycin resistance (Howden et al., 2008b). The
G223D mutation in walK and the K208R mutation in walR
were associated with increased vancomycinMICs (Howden et al.,
2011; Shoji et al., 2011). The rpoB gene, which encodes an
RNA polymerase subunit, also plays an important role in the
evolution of VISA (Matsuo et al., 2011). The H481Y mutation
in rpoB has been confirmed by allelic replacement experiments
to increase vancomycin resistance during development of the
VISA phenotype in theMu3 (hVISA) strain (Matsuo et al., 2011).
The majority of previous reports on the genetic mechanism
of VISA development have focused on clinical MRSA strains
(Doddangoudar et al., 2012). The development of vancomycin
non-susceptibility might be affected by methicillin or other drug
resistance, and so VISA development in methicillin-susceptible
strains warrants investigation.
In this study, 39 methicillin-susceptible S. aureus and 3
MRSA strains were treated with increasing concentrations of
vancomycin in vitro to investigate the genetic mechanism
underlying development of vancomycin resistance. The genes
(rpoB, vraS, graSR, and walRK) important for development of
vancomycin non-susceptibility were analyzed after 60 days of
vancomycin treatment and compared with those in the parental
strains. Our results suggest that four novel mutation sites are
important for VISA development: L466S in rpoB, R232K in graS,
I594M in walK, and A111T in walR.
MATERIALS AND METHODS
Bacterial Strains
Forty-two VSSA strains (numbered as S1–S42) used in this study
were purchased from the China General Microbiological Culture
Collection Center, China Center of Industrial Culture Collection,
Agricultural Culture Collection of China, China Forestry Culture
Collection Center, China Center for Type Culture Collection,
China Pharmaceutical Culture Collection, National Center for
Medical Culture Collections, and China Agricultural University.
All strain’s background were described in Table 1. Only S22 and
S24 were obtained from patients, others were separated from
animals or environment. Among these 42 strains, three were
MRSA (S3, S34, and S37). All strains were stored at−80◦C.
Antimicrobial Susceptibility Testing
The vancomycin MICs of all S. aureus parental strains
were determined by standardized agar dilution methods,
according to the CLSI guidelines (Cockerill, 2012). E-tests
were performed using glycopeptide resistance detection strips
(bioMérieux), including vancomycin, oxacillin, rifampicin,
teicoplanin, according to the manufacturer’s instructions. For
determination of MICs, a single colony was inoculated in
brain-heart infusion (BHI) broth (Oxoid, Basingstoke, UK) and
incubated at 37◦C. At a cell density of 0.5 McFarland units
(108 CFU/mL), bacteria were streaked evenly onto Mueller-
Hinton agar (Oxoid, Basingstoke, UK) plates. Plates were
incubated at 37◦C, and the MICs were read after 18–24 h of
incubation.
In vitro Development of Vancomycin
Non-susceptibility
All S. aureus strains were incubated on BHI agar (Oxoid,
Basingstoke, UK) plates with vancomycin (Sigma-Aldrich, St.
Louis, MO, USA) at 50% of the initial MIC. Plates were
incubated at 37◦C, and the strains were passaged to freshmedium
containing the same vancomycin concentration every 24 h. MICs
were re-determined after 4 days of treatment using the E-test
method. The vancomycin concentration was increased to 50% of
the newMIC level of each strain. This process was repeated every
4 days for 60 days. Stability of VISA strains was then determined
by passaging onto vancomycin-free agar plates every 24 h for
60 days.
Sequence Analysis and Mutation Detection
To identify the point mutations and amino acid changes between
60-day-treated and parental strains, the rpoB, vraS, graS, graR,
walK, and walR genes of all treated and parental strains were
amplified using the primers shown in Table 2. One colony of
each strain was treated with lysostaphin and lysozyme, and
genomic DNA was extracted using a TIANamp bacteria DNA kit
(Tiangen, China) according to the manufacturer’s instructions.
PCR amplification using genomic DNA as the template was
performed using Ex Taq DNA polymerase (Takara Shuzo Co.,
Ltd, Kyoto, Japan). The amplification conditions for rpoB, graS,
and walK were as follows: 94◦C for 3 min, 30 cycles of 94◦C for 1
min, 55◦C for 1 min, and 72◦C for 1 min, followed by a final step
at 72◦C for 7 min. The amplification conditions for vraS, graR,
and walR were as follows: 94◦C for 3 min, 30 cycles of 94◦C for
1 min, 57◦C for 1 min, and 72◦C for 1 min, followed by a final
step at 72◦C for 7 min. PCR products were purified, and their
sequences were analyzed. Nucleotide and amino acid sequence
comparisons of each pair of treated and parental strains were
performed using DNAMAN8.0 (Lynnon Biosoft, USA). Based on
the amino acid sequence alignment, the missense mutations were
analyzed by Jonckheere-Terpstra trend test.
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TABLE 1 | All strains’ background.
Strain ID Provider Strain ID Provider
S1a 21676b CICC S22 23656 (ATCC 25923) CICC
S2 21600 (ATCC 27217c) CICC S23 22944 CICC
S3 01334 ACCC S24 1.2465 (ATCC 6538) CGMCC
S4 01340 ACCC S25 AB 91119 CCTCC
S5 01332 ACCC S26 10201 CICC
S6 01331 ACCC S27 10499 (ATCC 12600) ACCC
S7 01339 ACCC S28 01012 ACCC
S8 10341 CFCC S29 141405 CPCC
S9 1.8721 (ATCC 29213) CGMCC S30 26003 CMCC
S10 1.1697 CGMCC S31 26112 CMCC
S11 1.1476 CGMCC S32 01011 ACCC
S12 141396 CPCC S33 26001 CMCC
S13 140594 CPCC S34 141431 CPCC
S14 140575 CPCC S35 140660 CPCC
S15 21648 CICC S36 1.1529 CGMCC
S16 10786 CICC S37 P1 CAU
S17 22942 CICC S38 AB18 CAU
S18 AB 94004 CCTCC S39 CD1 CAU
S19 AB 91093 CCTCC S40 CD9 CAU
S20 AB 91053 CCTCC S41 CD7 CAU
S21 23699 CICC S42 01336 ACCC
aStrain number; bCenter ID; cATCC ID.
CICC, China Center of Industrial Culture Collection; ACCC, Agricultural Culture Collection of China; CFCC, China Forestry Culture Collection Center; CPCC, China Pharmaceutical
Culture Collection; CMCC, National Center for Medical Culture Collections; CCTCC, China Center for Type Culture Collection; CGMCC, China General Microbiological Culture Collection
Center; CAU, China Agricultural University.
TABLE 2 | Sequences of Primers.
Gene 5′–3′ primer sequence Product length (bp)
vraS F GACGTAGAGGTGATTTATCGATGAACCACT 1044
vraS R TTAATCGTCATACGAATCCTCCTTATTTAA
graS F ATGAGTATGGAACTTGGCGCA 1592
graS R TTCCCAGATCCAGAGGGACC
graR F GGATTAAAGATTTTCAAAGTC 675
graR R GAGATTTCAAAAAATAAGCTAC
walR F ACCAGGTTGGACAGAAGACG 2000
walR R TGTGCATTTACGGAGCCCTT
walK F CGCGTAGAGGCGTTGGATA 1983
walK R TGGCTGTCATAGGTGTCGTT
rpoB F1 GCAAGGTATGCCATCTGCAAAG 1954
rpoB R1 TTGCTTCGGCGATACATCCA
rpoB F2 ACGTGAACGTGCTCAAATGG 2262
rpoB R2 ATGCCTTTGTAGCGAACACG
The presence of mecA and vanA in all strains was detected
as described previously using the following primers: mecA
forward 5′-TGGCTATCGTGTCACAATCG-3′; reverse 5′-CT
GGAACTTGTTGAGCAGAG-3′; vanA forward 5′-ATGAATAG
AATAAAAGTTGC-3′; reverse 5′-TCACCCCTTTAACGCTAA
TA-3′ (Saha et al., 2008). The multilocus sequence typing (MLST)
genotypes of all strains were also determined as described
(Enright et al., 2000). Seven housekeeping genes of all parental
strains were sequenced to obtain the sequence type (ST) of each
strain.
Statistical Analysis
Based on the relationships between the MICs and time points
during the vancomycin treatment, the 42 strains were grouped
by hierarchical clustering (Tibshirani et al., 2001). After the
in vitro treatment, genotypes were coded as 0, 1, or 2 for
each SNP in sequenced genes. The association between each
mutation site and MICs measured after 60 days vancomycin
treatment was analyzed using the Jonckheere-Terpstra (JT) trend
test (Jonckheere, 1954). P < 0.05 were considered to indicate
significance. All statistical analyses were performed using the R
statistical software (version 2.1).
RESULTS
Development of Vancomycin-Intermediate
Resistance in S. aureus In vitro
Forty-two VSSA strains were treated with vancomycin in vitro
for 60 days. After induction, although the MICs varied, only
the MIC of the S10 strain remained unchanged compared
with its parental strain. In contrast, the MICs of many strains
increased significantly (Figure 1). Twenty-nine VISA strains
were generated within 60 days, while 13 strains remained
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FIGURE 1 | Hierarchical clustering of 42 strains. Based on the association between MICs and time point, the entire 42 strains were grouped into 5 clusters by
hierarchical clustering.
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vancomycin susceptible (MIC < 4 µg/mL). The maximum MIC
of 16 µg/mL was achieved in 4/29 strains: S8, S15, S16, and
S41. The MICs of these four strains met the standard for VRSA
rather than VISA strains; however, the vanA gene cluster, a
common vancomycin-resistance determinant, was absent (data
not shown). The MICs of all strains were listed in Table 3.
Based on the relationships between the MICs and time
points, the 42 strains were grouped into five clusters by
hierarchical clustering (Figure 1). Eight strains were found in
C1 and C2 and showed the highest MICs (12–16 µg/mL).
These strains exhibited rapid development of vancomycin-
intermediate resistance, which was accompanied by several
common mutations in sequenced genes, such as L466S and
H481N in rpoB, R232K in graS, R222K, A468T, and I594M in
walK, and A111T in walR (Table 3).
The third cluster comprised 10 strains. The MICs of these
strains increased gradually over time, reaching 6–12 µg/mL.
Twenty-three strains, including 12 VSSA strains, were grouped
in C4 and exhibited slow development of vancomycin non-
susceptibility, resulting in MICs of 3–8 µg/mL. Only the MIC of
S11, which harbored the A243T mutation in walK, increased to 8
µg/mL (Table 3). Only strain S10 was grouped in C5. The MIC
of S10 was unchanged after the 60 days of treatment.
The sequence type (ST) of all parental strains was shown in
Table 3. Most (8/9) of the strains with MICs ≥ 12 µg/mL were
assigned to different ST types.
Antibiotic Susceptibilities of All S. aureus
Strains
To determine susceptibilities to other antibiotics after 60 days
of treatment, the oxacillin, rifampicin, and teicoplanin MICs of
all strains were measured by the E-test. The MICs of several
strains from each cluster are shown in Table 4. All of the 42
VSSA parental strains were initially susceptible to teicoplanin,
three (S3, S34, and S37) were resistant to oxacillin, and two
(S3 and S16) were resistant to rifampicin. After vancomycin
treatment, the teicoplanin MICs of most strains increased, while
the oxacillin and rifampicinMICs of most strains did not change.
In contrast, the oxacillin MICs of five strains (S3, S15, S16, S34,
and S37) decreased. Three VISA strains (S1560, S3560, and S3760)
became resistant to rifampicin, and the five rifampicin resistant
strains carried Asn (N) in the 481st amino acid of rpoB (Table 3).
However, the parental strains S37 and S4160, which also carried
this Asn (N), were susceptible to rifampicin.
Amino Acid Mutations Involved in VISA
Development
The complete sequences of rpoB, vraS, graS, graR, walK, and
walR were amplified from all strains. Only missense mutations
were observed by amino acid sequence alignment between the
60 days’ vancomycin-treated strains and parental strains. A large
number of SNPs were detected, and the mutations varied among
the strains. Multiple nonsynonymous mutations in the six genes
are shown in Table 3.
In rpoB, we found 10 distinct amino acid changes in 13/29
(44.8%) VISA strains: F279L, L466S, H481N, T518M, D631E,
Y737F, R917S, D1046V, and T1182I/I1182T. No amino acid
substitution was found at the 466th or 481st locus in the
VSSA strains treated by vancomycin for 60 days. Notably, the
T1182I/I1182T mutations not only occurred frequently in VISA
strains but were also found in VSSA strains. In vraS, seven
distinct missense mutations were identified in 10/29 (34.5%)
VISA strains. No nonsynonymous SNPs were found in the other
VISA or VSSA strains. In the graRS operon, 19 distinct mutations
were identified in 20/29 (69.0%) VISA strains. The L26F/F26L,
I59L/L59I, and Y223D mutations were present in both VISA
and VSSA strains, while the D223Y and T224I mutations were
detected only in VSSA strains. Twenty-two of the 29 (75.9%)
VISA strains harboredmutations in thewalRK operon, including
23 distinct mutations in walK and 5 in walR. Among these
mutations, R222K, A468T, and I594M in walK and A111T in
walR occurred more frequently. Furthermore, all VSSA strains
lacked R222K, I594M, and A111T but carried several other
mutations.
Overall, three VISA strains (S15, S35, and S41) contained
the L466S and H481N mutations in rpoB, accompanied by
the mutations R232K in graS, R222K, A468T, and I594M in
walK, and A111T in walR and acquired high-level vancomycin
resistance (MIC ≥ 12 µg/mL). The walK mutation was carried
most frequently by VISA strains. A previous report stated that
mutations in walK were most frequent in 39 clinical VISA strains
from various countries (Shoji et al., 2011).
To analyze the associations between mutation sites and MICs,
strain genotypes were coded as 0, 1, or 2 for each mutation
in sequenced genes. The associations between mutations and
MICs at 60 days were analyzed using the Jonckheere-Terpstra
(JT) trend test. As shown in Figure 2, 10 mutations (L466S and
H481N in rpoB, V15G in vraS, L26F, I59L, Y223D, and R232K
in graS, R222K, and I594M in walK and A111T in walR) were
significantly correlated with the MIC differences, including four
novel mutation sites (L466S in rpoB, R232K in graS, I594M in
walK and A111T in walR). These four mutation sites were only
occurred in five strains with MICs ≥ 10 µg/mL and have not
been reported to date. The P values of all mutations in graR were
>0.05, indicating that this gene might be relatively unimportant
in the process of VISA development.
Stability of Vancomycin Non-susceptibility
To investigate the stability of vancomycin non-susceptibility,
strains were incubated on vancomycin-free agar plates for
another 60 days after the vancomycin treatment. The MICs of all
strains (except S10) decreased after the removal of vancomycin,
while S35 and S41 remained as VISA strains. Six genes (rpoB,
vraS, graS, graR, walK, and walR) were sequenced and compared
with the genes before vancomycin removal. The strains with
mutations were shown in Table 5; 27 reverse mutations and
13 random mutations were detected compared with those
vancomycin treated strains. Only the reverse mutation F10L in
walK might be related to a decrease in the MIC.
DISCUSSION
VISA strains are increasingly prevalent in the hospital setting
and are a major issue in the treatment of MRSA infections.
It has been suggested that the occurrence of VISA strains is
relatively frequent, representing a threat to public health (Sader
Frontiers in Microbiology | www.frontiersin.org 5 January 2017 | Volume 7 | Article 2163
Wang et al. Novel Mutations in VISA Development
TABLE 3 | Amino acids mutations in VISA development.
Cluster Strain STa MICb(µg/mL) RpoB vraS graR graS walK walR
C1 S15 97 1.5/16 L466Sc, H481N,
T1182I
V15G —d (Q148Q)e I59L, R232K R222K, A468T,
I594M
A111T
S16 239 1.5/16 —(S466S, N481N) G15V — (Q148Q) — (K232K) I594M, (K222K,
T468T)
A111T
S41 9 1.0/16 L466S, H481N V15G D148Q L26F, I59L,
R232K
R222K, A468T,
I594M
A111T
S28 943 1.5/14 T1182I Q126K K17E, (Q148Q) I59L, D97E L265R —
S23 943 1.0/12 T1182I T331I — (Q148Q) I193M — —
C2 S8 6 1.5/16 D1046V — — (D148D) L59I D266N —
S9 5 1.5/12 R917S — — (D148D) — G25A —
S32 243 1.5/12 F279L, I1182T — — (Q148Q) L26F, D97E T270S, (T468T) —
C3 S35 8 1.5/12 L466S, H481N V15G — (Q148Q) R232K R222K, K294N,
D302N, A468T,
I594M
A111T
S1 8 1.5/10 — — — (Q148Q) L59I — P216S
S3 239 1.5/10 T1182I, (S466S,
N481N)
— — (Q148Q) L26F, I59L,
R232K
— (K222K,
T468T)
—
S7 243 1.5/10 T518M — V136I, S207G, (Q148Q) L59I H385P, (T468T) —
S27 464 1.0/8 — — S79F, (Q148Q) — — A111V
S37 9 1.0/8 — (N481N) L105F — (D148D) L59I, E97D R264K, L265R,
D302N
—
S38 9 1.0/8 — — — (D148D) L59I, E97D — —
S39 9 1.0/8 — G92D — (D148D) L26F — —
S40 9 1.0/8 — — — (D148D) L26F, G209S L10F, S506Y,
S591F
—
S34 464 0.5/6 — — — (D148D) — — —
C4 S11 96 1.0/8 D631E, T1182I — — (D148D) F26L A243T —
S5 239 1.5/4 Y737F, I1182T G15V Q148H L59I K540R, G560C,
(T468T)
—
S13 464 1.5/4 — — — (Q148Q) — I183K, R265L,
H464Y
—
S17 943 1.5/4 T1182I — — (Q148Q) I59L, D97E — R119H
S19 464 1.0/4 — — — (Q148Q) — — F192L
S20 464 1.0/4 — — — (Q148Q) — T471I —
S21 464 1.5/4 — — — (Q148Q) — V15L, R265L —
S25 243 1.5/4 — — — (Q148Q) — — (T468T) —
S26 464 1.0/4 — G20A — (Q148Q) W158C L265R, T279I —
S31 464 1.5/4 — — — (Q148Q) — — (T468T) —
S42 5 1.5/4 — — — (D148D) F26L, R160H,
Y223D, I224T
D302N —
S2 5 1.5/3 — — — (D148D) — R265L —
S4 243 1.5/3 — — — (Q148Q) — — (T468T) —
S6 243 1.5/3 P945S, I1182T — — (Q148Q) I59L — (T468T) —
S12 464 1.5/3 — — — (Q148Q) F26L, L59I D290E —
S14 464 1.0/3 G1139V, T1182I — — (Q148Q) F26L R343H —
S18 96 1.0/3 T1182I — — (D148D) — R265L, R298M R222L
S22 243 1.5/3 T1182I — I136V, G207S, (Q148Q) T224I — (T468T) —
S24 464 1.5/3 I1182T — — (Q148Q) — — P216L
(Continued)
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TABLE 3 | Continued
Cluster Strain STa MICb(µg/mL) RpoB vraS graR graS walK walR
S29 464 1.5/3 — — — (Q148Q) — — —
S30 464 0.5/3 — — — (Q148Q) — — R107H
S33 30 1.0/3 — — — (Q148Q) F26L, Y223D L265R, L314P —
S36 770 0.5/3 — — — (D148D) L26F, D223Y — —
C5 S10 9 1.0/1 — — — (D148D) L26F, D223Y,
T224I
— K208N, P216Q
aST, sequence type.
bMIC (µg/mL), MICs of parental/vancomycin treated strains.
cBold indicates the novel mutations.
dDash indicates amino acids had no change after 60 days vancomycin treatment.
eParentheses indicates the amino acids remain unchanged.
TABLE 4 | Antibiotic susceptibilities changes of strains.
Cluster Straina MIC (µg/mL) Antibiotic susceptibility E-test MIC (µg/mL)
OXA RIF TEI OXA RIF TEI
C1 S15 1.5 S S S 1 0.064 2
S1560 16 S R I 0.5 >256 16
S16 1.5 S R S 1 >256 4
S1660 16 S R R 0.5 >256 16
S41 1 S S S 0.5 0.064 1
S4160 16 S S S 0.5 0.064 8
S28 1.5 S S S 0.25 0.064 4
S2860 14 S S I 0.25 0.064 16
C2 S8 1.5 S S S 0.5 0.064 2
S860 16 S S I 0.5 0.064 16
S9 1.5 S S S 0.25 0.064 2
S960 12 S S I 0.25 0.064 16
S32 1.5 S S S 0.125 0.064 2
S3260 12 S S I 0.125 0.064 16
C3 S3 1.5 R R S >256 >256 1
S360 10 R R S 32 >256 8
S34 0.5 R S S 32 0.064 0.5
S3460 6 R S S 8 0.064 4
S35 1.5 S S S 0.25 0.064 1
S3560 12 S R S 0.5 >256 8
S37 1 R S S >256 1 0.5
S3760 8 R R S 4 4 8
C4 S2 1.5 S S S 0.125 0.064 2
S260 3 S S S 0.25 0.064 2
S5 1.5 S S S 0.125 0.064 1
S560 4 S S S 0.125 0.064 2
S11 1 S S S 0.5 0.064 0.064
S1160 8 S S S 0.5 0.064 8
C5 S10 1 S S S 0.25 0.064 1
S1060 1 S S S 0.25 0.064 1
OXA, oxacillin; RIF, rifampicin; TEI, teicoplanin. S, susceptible; I, intermediate; R, resistant.
aNo subscript represents parental strains.
Subscript indicates strains treated by vancomycin for 60 days.
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FIGURE 2 | The significance of association between each mutation sites and MICs. Data was analyzed by Jonckheere-Terpstra (JT) trend test. The x axis
shown six sequenced genes and the y axis shown −log10 of the P values resulting from the JT trend test. Each dot represented a mutation site, and the number
beside the dot shown the amino acid position. P < 0.05 were considered significant. *The novel mutation sites found in this study.
et al., 2009). Prolonged vancomycin exposure in patients can
contribute to generation of VISA, resulting in treatment failure
(Liu et al., 2011). In addition, VISA can also be generated in
vitro from VSSA strains by exposure to vancomycin (Matsuo
et al., 2011; Doddangoudar et al., 2012). Previous studies of the
mechanisms of VISA development focused on clinical MRSA
strains (Doddangoudar et al., 2012), while few studies have
addressed VISA development in methicillin-susceptible strains.
In this study, 29 (69%) VISA strains were generated from 42 S.
aureus strains by vancomycin treatment for 60 days in vitro. Our
results suggest that seven mutation sites are important for VISA
development, including four novel mutations: L466S in rpoB,
R232K in graS, I594M in walK, and A111T in walR.
Hierarchical clustering which can directly decompose the
dataset into a set of disjoint clusters was performed to trace the
dynamic changes in VISA development, and investigate different
vancomycin non-susceptibility evolution patterns. The 42 strains
were grouped into five clusters, and the MICs of nine strains
(eight from C1 and C2 and one from C3) were ≥12 µg/mL
(Figure 1). Among those nine strains, only S28 and S23 were
assigned to the same ST type (Table 3). 38/42 parental strains
was susceptible to oxacillin, rifampicin and teicoplanin. The three
MRSA strains (S3, S34, and S37) were resistant to oxacillin,
and 2/42 strains (S3 and S16) were resistant to rifampicin.
Strains S3 and S16 developed high MICs (10–16 µg/mL) after
vancomycin treatment. Three methicillin-susceptible strains—
S8, S15, and S41—showed the highest MIC of 16 µg/mL. There
was no significant correlation between VISA development and
initial resistance to oxacillin, rifampicin or teicoplanin. The
oxacillin MICs of five strains (S3, S15, S16, S34, and S37)
decreased after vancomycin treatment. It has been suggested
that upon acquisition of vancomycin resistance, some strains
show a concomitant decrease in oxacillin resistance (Bhateja
et al., 2006), and a previous study reported that mutated graR
may impair oxacillin resistance (Neoh et al., 2008). In this
study, no graR mutation was detected in these five strains.
The H481Y/N mutation is located in the rifampin resistance-
determining region, and this locus has been reported repeatedly
in clinical rifampicin-resistant S. aureus strains (Aubry-Damon
et al., 1998; O’Neill et al., 2006; Mick et al., 2010). In this study,
five rifampicin-resistant strains harbored the Asn (N) mutation
in the 481st amino acid of rpoB (Table 3). However, the parental
strains S37 and S4160, which harbor Asn (N), were susceptible
to rifampicin. In summary, no significant association was found
between these mutations and antibiotic susceptibility changes.
The genetic basis for vancomycin resistance in VISA remains
unclear. The rpoB, vraSR, graSR, and walRK genes have been
reported to be highly associated with vancomycin resistance. In
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TABLE 5 | Mutations after removal of vancomycin.
Cluster Strain MIC (µg/mL)a rpoB vraS graR graS walK walR
C1 S15 3 I1182Tb —c — — — —
S16 3 — — — — — —
S41 8 — — — — — —
S28 3 I1182T — — — R265L, A554G —
S23 3 — — — — — —
C2 S8 2 — — — — N266D —
S9 3 — — — — — —
S32 2 — — — E97D L265R —
C3 S35 6 — — — — N294K, N302D —
S1 2 — — — — — —
S3 2 I1182T — — — — —
S7 2 — — — — — —
S27 3 I1182T — — — — —
S37 3 — — — — K264R, R265L, N302D —
S38 2 — — — — — —
S39 2 T1182I — — — — —
S40 1 — — — — F10L, Y506S, F591S —
S34 1 — — — — — —
C4 S11 3 — — — — — —
S5 3 — — H148Q, V136I, S207G F26L — —
S13 2 — — — — — —
S17 2 — — — — — —
S19 1 — — — — — L192F
S20 2 — — — — — —
S21 3 — — E15D — — —
S25 2 — — I136V, G207S — — —
S26 1 — — — — R265L —
S31 2 — — — — — —
S42 2 — S39F — — N302D —
S2 2 — — — — — —
S4 2 — — — — — —
S6 2 — — — — — —
S12 2 — — — — — —
S14 1 I1182T — — — — —
S18 2 I1182T — — — L265R —
S22 2 I1182T — V136I, S207G — — —
S24 2 — — — — — —
S29 2 — — — — — —
S30 1 I1182T — — — — —
S33 1 — — — — P314L —
S36 2 — — — — — —
C5 S10 1 I1182T — — — — N208K, Q216P
aMIC (µg/mL), MICs after vancomycin removal for 60 days.
bBold indicates reverse mutations.
cDash indicates the amino acids remain unchanged.
this study, the complete sequences of rpoB, vraS, graS, graR,
walK, and walR were analyzed and compared with those of
the susceptible parental strains. Seven mutations occurred more
frequently in strains with high MICs (12–16 µg/mL), including
L466S and H481N in rpoB, R232K in graS, R222K, A468T, and
I594M inwalK, and A111T inwalR (Table 3). In vitro experiment
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and JT trend test indicated that four novel mutation sites were
important for VISA development—L466S, R232K, I594M, and
A111T—which were first reported in this study (Figure 2).
Alam et al. reported that rpoB H481 is the predominant
locus associated with an increased vancomycin MIC (Alam et al.,
2014). The mutations H481Y/N in rpoB play a dual role in
rifampin and vancomycin resistance (Watanabe et al., 2011; Gao
et al., 2013). Moreover, it has been suggested that the rpoB
mutation itself, and not any other incidental genetic change
caused by rifampin resistance, was responsible for the decreased
vancomycin susceptibility (Matsuo et al., 2011). In this study,
two mutations (L466S and H481N) were significantly associated
with increased vancomycin MICs. Although the L466S mutation
had not been reported previously, it might be important for the
development of VISA.
In vraS, the 15th amino acid locus was significantly associated
with MIC according to the JT trend test, but both the V15G
and G15V mutations were detected in different VISA strains.
Therefore, V15G/G15V seemed to be less important in VISA
development.
D148Q mutation in graR was reported previously to be
important for development of high-level resistance (Neoh et al.,
2008; Doddangoudar et al., 2012). In this study, only the S41
strain contained the D148Q mutation in graR (MIC = 16
µg/mL), while 28/42 (66.7%) VSSA parental strains initially
harbored Gln (Q) at locus 148. Therefore, we speculated that
the D148Q mutation in graR did not significantly affect the
development of vancomycin resistance. The S79F mutation is
important in the development of VISA strains (Neoh et al.,
2008; Shoji et al., 2011; Doddangoudar et al., 2012; Hafer et al.,
2012). Among our strains, only S27 carried the S79F mutation,
and exhibited a MIC of 8 µg/mL. According to the JT trend
test, no mutation in graR and four mutations (L26F, I59L,
Y223D, and R232K) in graS were significantly related to elevated
vancomycin MICs. However, the L26F/F26L, I59L/L59I, and
Y223D mutations were detected in both VISA and VSSA strains.
Thus, these mutation sites were unlikely to be responsible for
VISA development. The R232K mutation occurred frequently
(3/9) in strains with highMICs (12–16µg/mL) and was absent in
VSSA strains. This suggests that the R232K mutation is involved
in the development of vancomycin-intermediate resistance.
G223D mutation in walK and K208R mutation in walR were
associated with increased vancomycin MICs (Howden et al.,
2011; Shoji et al., 2011). However, these genetic changes are not
observed frequently in clinical and laboratory S. aureus strains
(Howden et al., 2008a,b; Kato et al., 2010). Shoji et al. collected
39 clinical VISA strains from various countries worldwide and
then analyzed the complete sequences of vraSR, graSR, clpP, and
walRK. Nine of the 39 (23%) VISA strains from four countries
harbored R222K and A468T mutations in walK. The L10F and
A243T mutations in walK and P216S in walR have been reported
previously in VISA strains (Shoji et al., 2011; Hafer et al., 2012). In
this study, 3/9 VISA strains with MICs≥ 12 µg/mL harbored the
R222Kmutation, S3 and S16 initially carried Lys (K) at locus 222.
The A468T mutation occurred in the same three VISA strains as
R222K, while other ten strains carried Thr (T) including seven
VISA strains initially (Table 3). Therefore, A468T seemed to be
important for VISA development. According to the JT trend test,
R222K, I594M in walK and A111T in walR were significantly
associated with vancomycin resistance. Although the mutations
I594M in walK and A111T in walR have not been reported to
date, they were frequently detected (4/9) in strains with MICs ≥
12 µg/mL. The presence of I594M and A111T in the same strain
may result in development of the VISA phenotype.
Overall, seven amino acid changes—L466S, H481N, R232K,
R222K, A468T, I594M, and A111T—were detected frequently
in our VISA strains. Although the four novel non-synonymous
mutations L466S, R232K, I594M, and A111T have not been
reported to date, we speculate that these mutations may play an
important role in development of VISA strains, together with the
H481N, R222K, and A468T mutations, synergistically promote
and maintain high-level vancomycin resistance. Several other
mutations were detected in both VISA and VSSA strains or in
only VSSA strains. Whether these mutations affect development
of a VISA phenotype remains unknown. Notably, certain VISA
strains did not harbor any important mutations within the
sequenced genes. The increased MICs of these strains may be
caused by mutations in other undetected/unidentified genes,
such as the proteolytic regulatory gene clp (Shoji et al., 2011) and
the accessory gene regulator agr (Sakoulas et al., 2002, 2005).
After removal of vancomycin for 60 days, the MICs of all
strains decreased. The L10F mutation in walK has been reported
previously in VISA strains, thus, the reverse mutation F10L in
walK might be associated with loss of vancomycin resistance.
These findings suggest that VISA development is affected by
a complex gene regulatory network, although other genes or
pathways might be involved in decreased MICs observed. The
presence of stop codons in vraS and graR was reported to be
related to loss of vancomycin non-susceptibility (Doddangoudar
et al., 2012). However, no stop codon was detected in this study.
In conclusion, this study demonstrated that prolonged
vancomycin exposure leads to development of vancomycin-
intermediate resistance in methicillin-susceptible S. aureus
strains. Compared with the susceptible parental strains, four
novel missense mutations—L466S in rpoB, R232K in graS,
I594M in walK and A111T in walR—were detected in high-level
vancomycin-resistant strains. Our results also suggest that rpoB,
graS, walK and walR are more important than vraS and graR in
the evolution of vancomycin non-susceptibility.
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